NeuroMetrix Reports Q3 2024 Business Highlights
05 nov. 2024 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The...
NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options
06 août 2024 07h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. today reported financial and business highlights for the quarter and six months ended June 30, 2024.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
15 févr. 2024 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
13 févr. 2024 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain...
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
12 déc. 2023 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with Long COVID.
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
05 déc. 2023 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
23 oct. 2023 11h13 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. announced today that it plans to issue its Q3 2023 business and financial highlights on October 26, 2023 at 8:00 a.m., Eastern Time.
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
31 mai 2023 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial...
NeuroMetrix Reports Q1 2023 Financial Results
03 mai 2023 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company’s mission is to...
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
21 mars 2023 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in...